Drug Trial Radar · NCT07793435
A Phase 1/2 Trial of ADI-212 in mCRPC
Last checked: Nov 19, 2026Latest source record: Sep 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
12
Planned (sponsor's estimate)
Start
Sep 2026
Primary completion
Oct 2028
Study completion Oct 2029
Sponsor
- Lead sponsor
- Adicet TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Aug 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 1/2 multicenter, open-label, dose finding and dose expansion study of ADI-212 in participants with metastatic castration-resistant prostate cancer (mCRPC)
Conditions
- Prostate Cancer Metastatic
Interventions
ADI-212Drug
Allogeneic cell therapy
FludarabineDrug
Chemotherapy for Lymphodepletion
CyclophosphamideDrug
Chemotherapy for Lymphodepletion
Primary outcomes
What the sponsor says the trial is designed to measure.
- The incidence of Subjects with Dose Limiting Toxicity within each dose levelTime frame: Day 42
- Proportion of treatment emergent and treatment related Adverse EventsTime frame: 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Adicet Clinical Trials
Redwood City, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.